by InSitu Biologics | Apr 15, 2021 | General
InSitu Biologics is off to a fast start in 2021. We completed a successful financing round, made great strides in our R&D efforts, and held our first Medical Advisory Board meeting. For additional information regarding our progress, please take some time to read...
by InSitu Biologics | Dec 18, 2020 | General
Insitu Biologics had several key accomplishments in 2020, setting the stage for an even better 2021. We significantly reduced our shareholders-of-record, renegotiated and renewed our license agreement with LifeCore Biomedical, and conducted successful bench and animal...
by InSitu Biologics | Aug 15, 2020 | General
InSitu Biologics has made considerable progress executing our business plan over the past several months, even in the midst of ongoing COVID-19 challenges. We recently raised over $2 million in a convertible note financing round, received a pre-investigational new...
by InSitu Biologics | Apr 10, 2020 | General
InSitu Biologics has continued to make great strides over the past few months. We have successfully submitted our Pre-IND application to the FDA, as well as applied for a National Institute of Health federal grant to support our development costs. During this time of...
